OGEN Oragenics Inc.

-0.02  -3%
Previous Close 0.55
Open 0.57
Price To Book 1.07
Market Cap 24298546
Shares 46,124,803
Volume 4,466,961
Short Ratio 0.67
Av. Daily Volume 1,860,168

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due early 2020.
Oral mucositis (OM)

Latest News

  1. Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis
  2. Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract
  3. Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98%
  4. OGEN: 60th Patient Enrolled into Phase 2 Trial of AG013; Data in 1H2020…
  5. Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019
  6. Oragenics, Inc. Enters into Collaboration with Florida International University to Expand Its Pipeline of Lantibiotics
  7. Oragenics Announces Closing of $12.5 Million Underwritten Public Offering
  8. Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering
  9. 6 Stocks Moving In Wednesday's After-Hours Session
  10. Organics Announces Proposed Underwritten Public Offering
  11. Four Healthcare Stocks Heating Up On Monday
  12. Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
  13. Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 - 19, 2019
  14. How Much Are Oragenics, Inc. (NYSEMKT:OGEN) Insiders Spending On Buying Shares?
  15. OGEN: New Preclinical Research Confirms OG716 Potential in Treating C. Difficile Infection…
  16. Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716
  17. Oragenics Inc. to Present at NobleCon15 on January 28, 2019
  18. Oragenics Fast Track Drug AG013 Going into Phase II Clinicals, Pipeline Review
  19. Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma
  20. Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives